Hoover S K, Inge T H, Frank J L, McKinnon G, Monaco J, Susskind B, Bear H D
Massey Cancer Center, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
Arch Surg. 1991 Apr;126(4):447-52. doi: 10.1001/archsurg.1991.01410280045006.
Tumor-specific T-cell clones were derived from spleen cells of mice bearing a syngeneic PHS-5 tumor (a P815 mastocytoma mutant). Cells were expanded in vitro and characterized and assayed for activity against the relevant tumor in vivo. Clone cells were CD4-, CD8+ T lymphocytes, as determined by fluorescence activated cell sorting analysis and were specifically cytotoxic against P815 tumor cells in vitro, as shown in chromium 51 release assays. These cells require both antigen and interleukin 2 to proliferate; neither alone is sufficient, even with the addition of interleukin 1. In an experimental P815 liver metastasis model, the adoptive transfer of GD11 or GD11.17 clone cells and injection of recombinant interleukin 2 (7500 U intraperitoneally) 3 days after infusion of tumor cells reduced the number of tumor nodules, while the adoptive transfer of lymphokine-activated killer cells was ineffective.
肿瘤特异性T细胞克隆源自携带同基因PHS - 5肿瘤（P815肥大细胞瘤突变体）的小鼠脾脏细胞。细胞在体外扩增，进行表征，并检测其对体内相关肿瘤的活性。通过荧光激活细胞分选分析确定，克隆细胞为CD4阴性、CD8阳性T淋巴细胞，如在51铬释放试验中所示，它们在体外对P815肿瘤细胞具有特异性细胞毒性。这些细胞增殖需要抗原和白细胞介素2；单独任何一种都不足够，即使添加白细胞介素1也不行。在实验性P815肝转移模型中，在注入肿瘤细胞3天后，过继转移GD11或GD11.17克隆细胞并腹腔注射重组白细胞介素2（7500 U）可减少肿瘤结节数量，而过继转移淋巴因子激活的杀伤细胞则无效。
